AbbVie v. Teva Pharmaceutical: Elagolix Patent Dismissed Without Prejudice in 56 Days
AbbVie filed suit against Teva in Delaware asserting US11690845B2, covering its elagolix-based hormone therapy combination capsules. Within 56 days, the parties resolved a threshold jurisdictional dispute via stipulation, dismissing Teva Ltd. without prejudice while the core ANDA infringement case presses forward against Teva Inc.
Jurisdictional manoeuvre ends Teva Ltd.’s role in AbbVie’s elagolix ANDA case
On November 7, 2023, AbbVie, Inc. filed a patent infringement complaint in the U.S. District Court for Delaware against Teva Pharmaceutical Industries, Ltd. (Teva Ltd.) and Teva Pharmaceuticals, Inc. (Teva Inc.), asserting US11690845B2. The patent covers a combination hormonal therapy comprising elagolix sodium (equivalent to 300 mg base), estradiol (1 mg), and norethindrone acetate (0.5 mg) in oral capsule form — the active ingredients associated with AbbVie’s Oriahnn product line targeting endometriosis-related heavy menstrual bleeding.
The case closed on January 2, 2024 — just 56 days after filing — through a court-approved stipulation. The stipulation resolved a disputed threshold question: whether Teva Ltd., the Israeli parent entity, was a proper defendant. Rather than litigating that issue, both sides agreed to dismiss Teva Ltd. without prejudice. Critically, Teva Ltd. agreed to be bound by any judgment entered against its U.S. affiliate, Teva Inc., with respect to ANDA No. 217650, effectively preserving AbbVie’s enforcement reach without keeping the parent entity formally in the case.
The 56-day resolution of this partial dismissal is notably fast, though it reflects a procedural — not substantive — resolution; the underlying ANDA infringement action against Teva Inc. continues. The stipulation suggests both parties weighed the cost and delay of motion practice on jurisdiction against the practical benefit of streamlining the defendant structure. What remains unknown from the public record is the status or timeline of the continuing case against Teva Inc., and whether settlement discussions are ongoing in parallel.
Filing to voluntary dismissal in 56 days
Case closed in 56 days — well ahead of typical ANDA district court timelines
Teva Ltd. dismissed without prejudice by stipulation — ANDA case continues
Dismissal under Fed. R. Civ. P. 41(a)(2) — court-approved
AbbVie dismissed Teva Ltd. pursuant to Rule 41(a)(2), which requires court approval when the defendant has appeared. This mechanism gives the court discretion over terms. Here, the stipulation was designed to be mutually beneficial: AbbVie shed a jurisdictionally contested defendant while preserving enforcement rights through Teva Ltd.’s binding-judgment agreement tied to ANDA No. 217650.
Procedural dismissal, not merits rulingWithout prejudice: AbbVie can refile against Teva Ltd. if needed
A dismissal without prejudice means AbbVie is not barred from reasserting claims against Teva Ltd. in a future action. This is significant here because Teva Ltd. maintained it was not a proper defendant — a dispute the parties explicitly chose not to resolve. The public record leaves open whether AbbVie would ever need to refile, given Teva Ltd.’s binding-judgment commitment on the ANDA at issue.
Refiling right preserved for AbbVieTeva Ltd. remains bound by any Teva Inc. judgment on ANDA 217650
The stipulation’s most commercially consequential term is paragraph 1: Teva Ltd. agreed to be bound by any judgment, order, or injunction entered against Teva Inc. regarding ANDA No. 217650. This means AbbVie retains practical enforcement reach over the parent entity without bearing the cost of litigating jurisdiction. Teva Ltd. also waived future personal jurisdiction and venue objections for enforcement purposes.
Parent bound by affiliate’s judgmentCore ANDA infringement case against Teva Inc. continues
This dismissal resolves only the defendant-structure dispute. The patent infringement action under ANDA No. 217650 — Teva’s application to market a generic version of the elagolix-based combination product — remains live against Teva Inc. In Hatch-Waxman ANDA litigation, the 30-month stay and regulatory timeline give strategic weight to even procedural case developments, as delays can affect generic market entry dates.
ANDA infringement case ongoingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Global biopharmaceutical company — holder of US11690845B2 covering elagolix hormone therapySearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Teva Pharmaceutical Industries Ltd. — global generic drug manufacturer, Israeli parent entitySearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Nathan Roger Hoeschen | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulation does not resolve any merits question — it is purely a case-management agreement governing the defendant structure. Teva Ltd.’s dismissal without prejudice preserves AbbVie’s litigation optionality while Teva Ltd.’s binding-judgment commitment on ANDA No. 217650 ensures AbbVie retains practical enforcement leverage over the parent. The explicit carve-out that the stipulation cannot be used to argue jurisdiction or venue in future proceedings suggests both parties anticipated the possibility of future disputes and drafted accordingly.
US11690845B2 — Elagolix Sodium Hormone Therapy Combination Capsules
US11690845B2 protects a specific oral pharmaceutical combination comprising elagolix sodium (equivalent to 300 mg base), estradiol (1 mg), and norethindrone acetate (0.5 mg), co-packaged in capsule form. Elagolix is a GnRH receptor antagonist developed by AbbVie for the management of heavy menstrual bleeding associated with uterine fibroids and endometriosis. The combination formulation — adding hormonal add-back therapy components to offset elagolix’s hypoestrogenic effects — represents a clinically and commercially significant innovation that differentiates the product from earlier elagolix-only formulations.
For the pharmaceutical sector, US11690845B2 represents a second-generation formulation patent that extends commercial protection beyond any earlier elagolix composition patents. This type of combination formulation patent is strategically valuable because it must be addressed by any ANDA filer seeking to copy the full commercial product, not just the active ingredient. Competitors in the women’s health and hormone therapy space — particularly those developing generic or biosimilar alternatives to GnRH antagonist-based therapies — should treat this patent as a key barrier asset in AbbVie’s elagolix defensive estate.
Should your team run an FTO analysis against US11690845B2?
Any pharmaceutical R&D team or generic drug developer working on elagolix-based formulations, GnRH antagonist combinations, or hormone add-back therapy co-packaged products should treat US11690845B2 as a priority FTO target. This case confirms AbbVie is actively enforcing this patent against ANDA filers — meaning a freedom-to-operate gap in your analysis could translate directly into a 30-month Hatch-Waxman stay and litigation costs. Product teams developing combination hormone therapies with similar active ingredient profiles should assess claim scope before finalising formulation decisions.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US11690845B2 against your target formulation, flag prosecution history estoppel risks, and identify prior art that may inform invalidity arguments. Eureka’s claim monitoring tools can also alert your team if AbbVie files continuation patents or divisional applications in the elagolix space — a common strategy for extending protection on blockbuster combination therapies. Run a full elagolix patent landscape search in Eureka to understand the estate before committing to an ANDA or 505(b)(2) development pathway.
Run a freedom-to-operate analysis on US11690845B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases in the hormone therapy sector
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the branded hormone therapy IP landscape
AbbVie’s aggressive ANDA defence posture on elagolix combination patents carries clear signals for generic entrants and branded competitors alike.
ANDA filers targeting elagolix combinations face active litigation risk
AbbVie filed suit within the Hatch-Waxman window, triggering the automatic 30-month stay on Teva’s ANDA No. 217650. Companies developing generics for elagolix-based hormone therapy combinations should expect similar enforcement responses and should map AbbVie’s full patent estate — including US11690845B2 — before committing to an ANDA strategy.
Stipulated binding-judgment clauses are an efficient alternative to jurisdictional motion practice
The Teva Ltd. stipulation illustrates a practical tool for managing multi-entity defendant structures in ANDA cases. Rather than filing motions to dismiss for lack of personal jurisdiction — which consume time within a stay period — parties can negotiate binding-judgment agreements that preserve plaintiff enforcement rights while simplifying the case caption. This approach is replicable and worth considering in multi-national generic company disputes.
AbbVie v Teva — key questions answered
Teva Pharmaceutical Industries Ltd. was dismissed without prejudice by stipulation on January 2, 2024, approximately 56 days after AbbVie filed suit. The dismissal was procedural — resolving a jurisdictional dispute over whether Teva Ltd. was a proper defendant — and does not reflect any ruling on the merits. The underlying ANDA infringement case against Teva Pharmaceuticals, Inc. continues.
AbbVie asserted US11690845B2, which covers an oral pharmaceutical combination comprising elagolix sodium (eq. 300 mg base), estradiol (1 mg), and norethindrone acetate (0.5 mg) capsules co-packaged with elagolix sodium capsules. This formulation corresponds to AbbVie’s Oriahnn product, used in treating heavy menstrual bleeding associated with uterine fibroids.
A dismissal without prejudice means AbbVie is not barred from refiling patent infringement claims against Teva Ltd. in a future action. However, Teva Ltd. agreed in the stipulation to be bound by any judgment entered against Teva Inc. regarding ANDA No. 217650 — effectively giving AbbVie enforcement reach over the parent entity without keeping it as a named defendant in the current action.
ANDA No. 217650 is Teva’s Abbreviated New Drug Application seeking FDA approval to market a generic version of AbbVie’s elagolix sodium/estradiol/norethindrone acetate combination oral capsules. AbbVie’s patent infringement suit was triggered by this ANDA filing under the Hatch-Waxman Act, which allows brand companies to sue ANDA filers and potentially invoke a 30-month regulatory stay on FDA approval of the generic.
Teva Ltd. is the Israeli parent entity of the Teva group. It asserted it was not a proper defendant in the U.S. action, raising a personal jurisdiction or proper-party dispute. Rather than litigating this through motion practice, both parties agreed to a stipulation under which Teva Ltd. was dismissed without prejudice but agreed to be bound by any judgment against its U.S. affiliate, Teva Inc., on the ANDA at issue. This preserved AbbVie’s enforcement position while simplifying the defendant structure.
PatSnap Eureka searches patents and litigation data to answer instantly.